Login / Signup

Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic.

Sajad KhialiElnaz KhaniSamineh B RouyTaher Entezari-Maleki
Published in: Future microbiology (2022)
Despite the progress in the management of COVID-19, effective oral antiviral agents are still lacking. In the present review, the potential beneficial effects of molnupiravir in the management of COVID-19 are discussed. A literature search in Google Scholar, Scopus, PubMed and clinicaltrials.gov for the relevant articles regarding the pharmacokinetics, pharmacodynamics and clinical trials of molnupiravir in the management of COVID-19 is conducted. Most of the preclinical studies and available clinical trials showed a favorable short-term safety profile of molnupiravir; however, given its possible genotoxic effects, further trials are required to confirm the long-term efficacy and safety of molnupiravir in patients with COVID-19.
Keyphrases
  • coronavirus disease
  • sars cov
  • clinical trial
  • respiratory syndrome coronavirus
  • systematic review
  • cell therapy
  • climate change